On October 1, 2021 the CNS is proud to announce a new and improved user experience for all your SANS education needs. You’ll retain access to any current subscriptions
but answers on exams won’t transfer over - so make sure you complete any exams and claim credit by September 30 or start the new SANS 2021 today

  • ENDOSCOPIC ENDONASAL APPROACH FOR PITUITARY ADENOMAS: A SERIES OF 555 PATIENTS

    Final Number:
    1443

    Authors:
    Alessandro Paluzzi MD; Paul A. Gardner MD; Juan Carlos Fernandez-Miranda MD; Matthew Tormenti; Maria Koutourousiou MD; Carl Snyderman MD

    Study Design:
    Other

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2012 Annual Meeting

    Introduction: The purpose of this study was to report the results of a consecutive series of patients who underwent an endoscopic endonasal approach (EEA) for resection of pituitary adenoma and to compare them to previous series of microscopic and endoscopic approaches.

    Methods: Clinical outcomes of a consecutive series of patients operated at our Cranial Base Center between 2002 and 2011.

    Results: 555 patients underwent an EEA for removal of a pituitary adenoma, 36 of which were lost to follow up. The mean follow up was 3.1 years (range 3 months to 9.5 years). Ninety-one patients (17.5%) were recurrent adenomas. Fifty-five patients (10.6%) had a microadenoma and 464 patients (89.4%) had a macroadenoma. The mean tumor volume was 8.7cm3. Reconstruction with a nasal septal flap was used in 238 cases (65.6%). The rate of gross total resection was 65.3% in the 359 patients with non-functioning adenomas. The remission rates with EEA alone were 81% in the 58 ACTH-secreting adenomas, 65.3% in the 49 GH-secreting adenomas and 54.7% in the prolactinomas. Of the 237 patients presenting with visual loss, 190 (80.2%) improved or completely resolved, 47 (19.8%) remained unchanged and none of them worsened permanently following EEA. The CSF leak rate was 5% and this improved from 11.5% before the introduction of the nasal septal flap to 3.3% after. Perioperative complications included meningitis (0.9%), tumor bed hematoma (1.1%), ICA injury (0.3%) and SIADH (0.7%). The rate of permanent DI was 2.5% and new anterior pituitary insufficiency 3.1%. Nasal morbidity included epistaxis (1%), sinusitis (0.8%) and anosmia (2.1%).

    Conclusions: The EEA is a safe and effective way to surgically approach pituitary adenomas, particularly in those with supra-sellar extension, cavernous sinus invasion and in recurrent adenomas. The remission rates and complication rates were comparable to the ones reported in previous series of microscopic and endoscopic approaches.

    Patient Care: This study has the potential to improve patient care by demonstrating a tendency for better preservation of the pituitary gland, pituitary stalk and optic apparatus

    Learning Objectives: To appreciate the advantages and the indications of the endoscopic endonasal approach for the removal of pituitary adenoma

    References:

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy